Heron Therapeutics Inc
NASDAQ:HRTX

Watchlist Manager
Heron Therapeutics Inc Logo
Heron Therapeutics Inc
NASDAQ:HRTX
Watchlist
Price: 1.385 USD -3.82%
Market Cap: $254m

Operating Margin

1%
Current
Improving
by 60.7%
vs 3-y average of -59.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
1%
=
Operating Income
$1.6m
/
Revenue
$155.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
1%
=
Operating Income
$1.6m
/
Revenue
$155.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Heron Therapeutics Inc
NASDAQ:HRTX
256.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.6B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
38th
Based on 14 112 companies
38th percentile
1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Heron Therapeutics Inc
Glance View

Market Cap
254m USD
Industry
Biotechnology

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 302 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

HRTX Intrinsic Value
2.334 USD
Undervaluation 41%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
1%
=
Operating Income
$1.6m
/
Revenue
$155.1m
What is Heron Therapeutics Inc's current Operating Margin?

The current Operating Margin for Heron Therapeutics Inc is 1%, which is above its 3-year median of -59.6%.

How has Operating Margin changed over time?

Over the last 3 years, Heron Therapeutics Inc’s Operating Margin has increased from -211.4% to 1%. During this period, it reached a low of -211.4% on Sep 30, 2022 and a high of 1% on Sep 30, 2025.

Back to Top